Arsenic Trioxide for Structural p53 Mutations
NCT04695223
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Arsenic Trioxide
p53 Mutations
Refractory Cancer
Intractable Cancer
Interventions
DRUG:
Arsenic Trioxide
Sponsor
Shanghai Changzheng Hospital